Concepedia

Michael Philip Sun

MP

Statistics

Publications

2

Citations

20

H-Index

2

Active since

2023

Affiliations

Cornell University(Current)

New York Hospital Queens

NewYork–Presbyterian Hospital

Presbyterian Hospital

Weill Cornell Medicine

Michael Philip Sun is an author at Cornell University specializing in health sciences, medicine, and treatment verification.

Top concepts

Publications per year

2023–2023

2

Publications

2

A phase I/II dose-escalation study of fractionated 225Ac-J591 for progressive metastatic castration-resistant prostate cancer (mCRPC) in patients with prior treatment with 177Lu-PSMA.

Jones T. Nauseef, Michael Philip Sun, Charlene Thomas et al. · Journal of Clinical Oncology · 2023 · 10 citations

Phase I dose-escalation results of prostate-specific membrane antigen-targeted radionuclide therapy (PSMA-TRT) with alpha-radiolabeled antibody <sup>225</sup>Ac-J591 and beta-radioligand <sup>177</sup>Lu-PSMA I&amp;T.

Scott T. Tagawa, Michael Philip Sun, Jones T. Nauseef et al. · Journal of Clinical Oncology · 2023 · 10 citations

, , +24

Rows per page

1–2 of 2